Clinical Candidate VT-1161's Antiparasitic Effect In Vitro, Activity in a Murine Model of Chagas Disease, and Structural Characterization in Complex with the Target Enzyme CYP51 from Trypanosoma cruzi

A novel antifungal drug candidate, the 1-tetrazole-based agent VT-1161 [(R)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(1H-tetrazol-1-yl)-1-{5-[4-(2,2,2-trifluoroethoxy)phenyl]pyridin-2-yl}propan-2-ol], which is currently in two phase 2b antifungal clinical trials, was found to be a tight-binding ligand...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Antimicrob Agents Chemother
Prif Awduron: Hoekstra, William J., Hargrove, Tatiana Y., Wawrzak, Zdzislaw, da Gama Jaen Batista, Denise, da Silva, Cristiane F., Nefertiti, Aline S. G., Rachakonda, Girish, Schotzinger, Robert J., Villalta, Fernando, Soeiro, Maria de Nazaré C., Lepesheva, Galina I.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society for Microbiology 2016
Pynciau:
Experimental Therapeutics
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4750653/
https://ncbi.nlm.nih.gov/pubmed/26643331
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02287-15
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg